{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T18:51:24Z","timestamp":1785783084620,"version":"3.56.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T00:00:00Z","timestamp":1543795200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s00345-018-2576-0","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T15:10:42Z","timestamp":1543849842000},"page":"1665-1670","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Efficacy and safety of mirabegron, a \u03b23-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study"],"prefix":"10.1007","volume":"37","author":[{"given":"Jee Soo","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Seung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cho Nyeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Woon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Won","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,3]]},"reference":[{"key":"2576_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.eururo.2015.04.015","volume":"68","author":"JS Liu","year":"2015","unstructured":"Liu JS, Dong C, Casey JT et al (2015) Quality of life related to urinary continence in adult spina bifida patients. Cent Eur J Urol 68:61\u201367","journal-title":"Cent Eur J Urol"},{"key":"2576_CR2","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s00467-008-0780-7","volume":"23","author":"TP Jong de","year":"2008","unstructured":"de Jong TP, Chrzan R, Klijn AJ et al (2008) Treatment of the neurogenic bladder in spina bifida. Pediatr Nephrol 23:889\u2013896","journal-title":"Pediatr Nephrol"},{"key":"2576_CR3","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/S0022-5347(06)00620-3","volume":"176","author":"AD Parekh","year":"2006","unstructured":"Parekh AD, Trusler LA, Pietsch JB et al (2006) Prospective, longitudinal evaluation of health related quality of life in the pediatric spina bifida population undergoing reconstructive urological surgery. J Urol 176:1878\u20131882","journal-title":"J Urol"},{"key":"2576_CR4","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0022-5347(05)64112-2","volume":"169","author":"CV Hopps","year":"2003","unstructured":"Hopps CV, Kropp KA (2003) Preservation of renal function in children with myelomeningocele managed with basic newborn evaluation and close followup. J Urol 169:305\u2013308","journal-title":"J Urol"},{"key":"2576_CR5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s11884-016-0371-6","volume":"11","author":"RM Sturm","year":"2016","unstructured":"Sturm RM, Cheng EY (2016) The management of the pediatric neurogenic bladder. Curr Bladder Dysfunct Rep 11:225\u2013233","journal-title":"Curr Bladder Dysfunct Rep"},{"key":"2576_CR6","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1124\/jpet.106.115840","volume":"321","author":"T Takasu","year":"2007","unstructured":"Takasu T, Ukai M, Sato S et al (2007) Effect of (R)-2-(2-aminothiazol-4-yl)-4\u2032-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 321:642\u2013647","journal-title":"J Pharmacol Exp Ther"},{"key":"2576_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/sc.2015.195","volume":"54","author":"J Wollner","year":"2016","unstructured":"Wollner J, Pannek J (2016) Initial experience with the treatment of neurogenic detrusor overactivity with a new \u03b2-3 agonist (Mirabegron) in patients with spinal cord injury. Spinal Cord 54:78\u201382","journal-title":"Spinal Cord"},{"key":"2576_CR8","first-page":"7","volume":"61","author":"N Wada","year":"2015","unstructured":"Wada N, Okazaki S, Kobayashi S et al (2015) Efficacy of combination therapy with mirabegron for anticholinergic-resistant neurogenic bladder: videourodynamic evaluation. Hinyokika Kiyo 61:7\u201311","journal-title":"Hinyokika Kiyo"},{"key":"2576_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.eururo.2016.02.007","volume":"70","author":"AS Blais","year":"2016","unstructured":"Blais AS, Nadeau G, Moore K et al (2016) Prospective pilot study of mirabegron in pediatric patients with overactive bladder. Eur Urol 70:9\u201313","journal-title":"Eur Urol"},{"key":"2576_CR10","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.urology.2014.09.001","volume":"84","author":"SW Kim","year":"2014","unstructured":"Kim SW, Choi JH, Lee YS et al (2014) Preoperative urodynamic factors predicting outcome of botulinum toxin-A intradetrusor injection in children with neurogenic detrusor overactivity. Urology 84:1480\u20131484","journal-title":"Urology"},{"key":"2576_CR11","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.jpurol.2012.10.019","volume":"9","author":"EK Choi","year":"2013","unstructured":"Choi EK, Hong CH, Kim MJ et al (2013) Effects of intravesical electrical stimulation therapy on urodynamic patterns for children with spina bifida: a 10-year experience. J Pediatr Urol 9:798\u2013803","journal-title":"J Pediatr Urol"},{"key":"2576_CR12","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0022-5347(06)00305-3","volume":"176","author":"T Neveus","year":"2006","unstructured":"Neveus T, Von Gontard A, Hoebeke P et al (2006) The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children\u2019s Continence Society. J Urol 176:314\u2013324","journal-title":"J Urol"},{"key":"2576_CR13","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.eururo.2015.07.071","volume":"69","author":"J Groen","year":"2016","unstructured":"Groen J, Pannek J, Castro Diaz D et al (2016) Summary of European Association of Urology (EAU) guidelines on neuro-urology. Eur Urol 69:324\u2013333","journal-title":"Eur Urol"},{"key":"2576_CR14","doi-asserted-by":"publisher","first-page":"e16718","DOI":"10.1371\/journal.pone.0016718","volume":"6","author":"TM Kessler","year":"2011","unstructured":"Kessler TM, Bachmann LM, Minder C et al (2011) Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. PLoS One 6:e16718","journal-title":"PLoS One"},{"key":"2576_CR15","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1002\/nau.20420","volume":"26","author":"O Yamaguchi","year":"2007","unstructured":"Yamaguchi O, Chapple CR (2007) Beta3-adrenoceptors in urinary bladder. Neurourol Urodyn 26:752\u2013756","journal-title":"Neurourol Urodyn"},{"key":"2576_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1177\/1756287209103937","volume":"1","author":"KE Andersson","year":"2009","unstructured":"Andersson KE (2009) Prospective pharmacologic therapies for the overactive bladder. Ther Adv Urol 1:71\u201383","journal-title":"Ther Adv Urol"},{"key":"2576_CR17","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1124\/jpet.108.138651","volume":"326","author":"LA Leon","year":"2008","unstructured":"Leon LA, Hoffman BE, Gardner SD et al (2008) Effects of the beta 3-adrenergic receptor agonist disodium 5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL-316243) on bladder micturition reflex in spontaneously hypertensive rats. J Pharmacol Exp Ther 326:178\u2013185","journal-title":"J Pharmacol Exp Ther"},{"key":"2576_CR18","first-page":"713","volume":"13","author":"P Tyagi","year":"2010","unstructured":"Tyagi P, Tyagi V (2010) Mirabegron, a \u03b23-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder. IDrugs 13:713\u2013722","journal-title":"IDrugs"},{"key":"2576_CR19","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.eururo.2012.10.016","volume":"63","author":"V Khullar","year":"2013","unstructured":"Khullar V, Amarenco G, Angulo JC et al (2013) Efficacy and tolerability of mirabegron, a \u03b2(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol 63:283\u2013295","journal-title":"Eur Urol"},{"key":"2576_CR20","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.juro.2012.10.017","volume":"189","author":"VW Nitti","year":"2013","unstructured":"Nitti VW, Auerbach S, Martin N et al (2013) Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 189:1388\u20131395","journal-title":"J Urol"},{"key":"2576_CR21","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.eururo.2012.10.048","volume":"63","author":"CR Chapple","year":"2013","unstructured":"Chapple CR, Kaplan SA, Mitcheson D et al (2013) Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a \u03b2(3)-adrenoceptor agonist, in overactive bladder. Eur Urol 63:296\u2013305","journal-title":"Eur Urol"},{"key":"2576_CR22","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/ijcp.12194","volume":"67","author":"VW Nitti","year":"2013","unstructured":"Nitti VW, Khullar V, van Kerrebroeck P et al (2013) Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, doubleblind, placebo-controlled, phase III studies. Int J Clin Pract 67:619\u2013632","journal-title":"Int J Clin Pract"},{"key":"2576_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/nau.22505","volume":"33","author":"CR Chapple","year":"2013","unstructured":"Chapple CR, Cardozo L, Nitti VW et al (2013) Mirabegron in overactive bladder: a review of efficacy, safety and tolerability. Neurourol Urodyn 33:17\u201330","journal-title":"Neurourol Urodyn"},{"key":"2576_CR24","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11934-013-0335-8","volume":"14","author":"KE Andersson","year":"2013","unstructured":"Andersson KE (2013) Beta3-receptor agonists for overactive bladder-new frontier or more of the same? Curr Urol Rep 14:435\u2013441","journal-title":"Curr Urol Rep"},{"key":"2576_CR25","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/bju.13988","volume":"120","author":"A Apostolidis","year":"2017","unstructured":"Apostolidis A (2017) Combination treatments for overactive bladder refractory to first-line pharmacotherapy: do they meet expectations? BJU Int 120:459\u2013460","journal-title":"BJU Int"},{"key":"2576_CR26","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1111\/ijcp.12433","volume":"68","author":"VW Nitti","year":"2014","unstructured":"Nitti VW, Chapple CR, Walters C et al (2014) Safety and tolerability of the \u03b23-adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised phase III trials and of a 1-year randomized phase III trial. Int J Clin Pract 68:972\u2013985","journal-title":"Int J Clin Pract"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-018-2576-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-018-2576-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-018-2576-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T16:34:52Z","timestamp":1582043692000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-018-2576-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,3]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["2576"],"URL":"https:\/\/doi.org\/10.1007\/s00345-018-2576-0","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,3]]},"assertion":[{"value":"12 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflicts of interest pertaining to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in the studies involving human participants were in accordance with the ethical standards of the institutional or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The Institutional Review Board of Yonsei University College of Medicine waived the requirement of obtaining informed consent because this study retrospectively reviewed anonymous patient data and did not involve a patient intervention or the use of human tissue samples.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}